Eli Lilly and Company

Tetraphase Pharmaceuticals, Inc.

Eccogene (shanghai) Co., Ltd.

Eccogene Inc.

Jingye Zhou

Yi Wei

Xiao-Yi Xiao

Louis Plamondon

Robert Zahler

David Andrew Coates

Roger B Clark

Diana Katharine Hunt

Luo Heng Qin

Tianwei Ma

Jiuxiang Zhu

Xuefeng Sun

Lian Zhu Liu

Zaifang Ren

Mingwei Zheng

Zhi Long Hu

Guoqiang Zhou

Koc Kan Ho

Mengyang Fan

Luoheng Qin

Qing Xu

Haizhen Zhang

Joyce A Sutcliffe

Magnus Ronn

Cuixiang Sun

Weiguo Quan

Yonghong Deng

Mi Zeng

Weiqiang Zhan

The application relates to a compound of Formula (I′) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I') or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.

Thyroid hormone receptor agonists and use thereof

The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.

Substituted imidazoles as GLP-1 receptor agonists

The application relates to a compound of Formula (I') or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I&#x2032;) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.

The present invention provides compounds which are of the formula (I) and (II) wherein X is selected from the group consisting of (III) and (IV); R is selected from the group consisting of (V) and (VI); Q is selected from the group consisting of (VII) and (VIII); and (IX) Ris selected from the group consisting of (X) and (XI); or a pharmaceutically acceptable salt thereof, methods for treating obesity, type II diabetes, and compositions. 

Pyrrolidinone compounds

The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.

Amino pyrimidine ssao inhibitors

The present invention provides compounds of the formula below pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.

Amino pyrimidine compounds useful as SSAO inhibitors

Amino pyrimidine SSAO inhibitors

The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds. 

The present invention provides compounds of the Formula below wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds.

Tetrahydropyranyl benzamide derivatives

The present invention provides compounds of the Formula (Ia) wherein R is selected from the group consisting of CH, CH(CH), CHCN, CHCHF, CHCF, (A), (B), (C), (D), (E), (F), CHCHOCH, and CHC(O)OCH(CH); Ris selected from the group consisting of CF, OCF, and Cl; Ris selected from the group consisting of H and F; or a pharmaceutically acceptable salt thereof. 

GPR142 agonist compounds

This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (MetAP2) and dipeptidyl peptidase-4 (DPP-4). MetAP2 is a metalloproteinase that cleaves initiator methionine from nascent peptide emerging from the ribosomes. WO 2010/065879 reports small molecule MetAP2 inhibitors for obesity treatment. DPP-4 inhibitors are an established drug class to improve glycemic control in patients with type 2 diabetes mellitus. Compounds with dual inhibitory activity in both MetAP2 and DPP-4 are desired. The present invention provides novel compounds with dual MetAP2 and DPP-4 inhibitition. These dual inhibitor compounds can be useful in the treatment of a MetAP2 and DPP-4 mediated condition. The present invention provides a compound of the following Formula (I); or a pharmaceutically acceptable salt thereof. In an embodiment of the invention, the compound is 

Pyrazole compounds

The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use. 

Tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

Growing community of inventors

Shanghai, China

Jingye Zhou